论文部分内容阅读
目的:探讨外周T细胞淋巴瘤-非特指型(PTCL-NOS)患者的临床疗效及其预后影响因素。方法:选择2010年1月至2018年12月，于河南省淋巴瘤诊疗中心收治的87例PTCL-NOS患者为研究对象。患者中位年龄为54岁(19～79岁)；男性患者为61例，女性为26例。采用回顾性分析方法，收集患者的一般临床资料，实验室及辅助检查结果等临床病例资料，并且分析患者的临床疗效、预后及其影响因素。采用Kaplan-Meier法绘制患者总体生存(OS)曲线，并且计算其1、3、5年OS率。采用log-rank检验，对可能影响患者OS率的临床特征进行单因素分析。采用多因素Cox比例风险模型，对单因素分析结果中有统计学意义的影响因素进行多因素分析。本研究遵循的程序符合2013年修订版《世界医学协会赫尔辛基宣言》要求，并且与所有患者签署临床研究知情同意书。结果:①本组87例患者中，接受CHOP(环磷酰胺+表柔比星+长春新碱+泼尼松)、GDPT(吉西他滨+顺铂+地塞米松+沙利度胺)及其他化疗方案治疗的患者分别为33例(37.9%)、33例(37.9%)和21例(24.1%)。②本组87例PTCL-NOS患者的客观缓解率(ORR)为75.9%，1、3、5年OS率分别为85.9%、50.2%和33.0%。③单因素分析结果显示，Ann Arbor分期(n χ2＝16.384，n P2分者预后较差。因此，应积极探索新的PTCL-NOS治疗方案，进一步改善患者的临床疗效及预后。“,”Objective:To explore clinical efficacy of different chemotherapy regimens and their prognostic factors of patients with peripheral T cell lymphoma-not otherwise specified (PTCL-NOS).Methods:From January 2010 to December 2018, a total of 87 patients with PTCL-NOS admitted to Lymphoma Diagnosis and Treatment Center of Henan Province were selected as research subjects. The median age of patients was 54 years (19-79 years). And there were 61 male patients and 26 females. By retrospective research methods, the general clinical data, laboratory and auxiliary examination results of PTCL-NOS patients were collected, and the efficacy, prognosis and it′s influencing factors were analyzed. Kaplan-Meier method was used to draw the overall survival (OS) curve of patients, and the 1, 3 and 5 years-OS rates were calculated. The log-rank test was used to conduct univariate analysis of clinical characters that might affect patients′ OS rates. Multivariate Cox proportional risk model was used to analyze the statistically significant factors in univariate analysis results. This study was in line with n World Medical Association Declaration of Helsinki revised in 2013 and informed contents were obtained from all patients.n Results:① Among the 87 patients in this study, the number of patients who treated with CHOP (cyclophosphamide+ doxorubicin+ vincristine+ prednisone), GDPT (gemcitabine+ cisplatin+ prednisone+ thalidomide) or other chemotherapy regimens were 33 cases (37.9%), 33 cases (37.9%) and 21 cases (24.1%), respectively. ② The objective response rate (ORR) of 87 patients with PTCL-NOS was 75.9% (66/87). And the 1, 3 and 5 years-OS rates were 85.9%, 50.2% and 33.0%, respectively. ③ The results of univariate analysis showed that Ann Arbor stage (n χ2=16.384, n P 2 scores have poor prognosis. Therefore, new treatment regiments should be actively explored to improve the clinical efficacy and prognosis of patients with PTCL-NOS.